MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

Search

Ipsen SA.

Abrir

SetorFinanças

115.5 -0.09

Visão Geral

Variação de preço das ações

24h

Atual

Mín

114.7

Máximo

116.1

Indicadores-chave

By Trading Economics

Rendimento

220M

334M

Vendas

-2.9M

1.8B

P/E

Médio do Setor

21.117

28.015

Rendimento de Dividendos

1.25

Margem de lucro

18.354

Funcionários

5,358

EBITDA

-73M

637M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+12.28% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.25%

3.82%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

88M

9.4B

Abertura anterior

115.59

Fecho anterior

115.5

Sentimento de Notícias

By Acuity

42%

58%

163 / 530 Ranking em Finance

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Ipsen SA. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de dez. de 2024, 07:05 UTC

Conversa de Mercado

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparação entre Pares

Variação de preço

Ipsen SA. Previsão

Preço-alvo

By TipRanks

12.28% parte superior

Previsão para 12 meses

Média 133.17 EUR  12.28%

Máximo 148 EUR

Mínimo 118 EUR

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Ipsen SA. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

4

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

99.85 / 104Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

163 / 530 Ranking em Finanças

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat